Saturday, October 10, 2026

Moderna Stock Went Up By Over 3% At Session Start On Monday

ViaNews Editorial Team

December 21, 2020

Moderna Stock Went Up By Over 3% At Session Start On Monday

Shares of Moderna rose 3.22% to $144.75 at 10:51 EST on Monday, following yesterday's downward trend. The Nasdaq Stock Market is sliding 1.67% to $12,542.00, following yesterday's downward trend, This seems, up to now, an all-around negative trend exchanging session today.

Moderna's last close was $140.23, 23.32% under its 52-week high of $178.50.

News about Moderna today

Philippines to start vaccine talks with Moderna by year-end: CNN. According to today's article on Bloomberg Quint, "The Philippines will start talks with Moderna Inc. on or before Dec. 30 to secure supply of the company's coronavirus vaccine, Foreign Affairs Secretary Teodoro Locsin said Monday.", ""Moderna is interested in giving an allocation," he said in a live-streamed interview with CNN Philippines, citing Philippine ambassador to the U.S. Jose Manuel Romualdez."

Moderna's Sales

Moderna's sales growth is 1665.3% for the ongoing quarter and 15909.5% for the next. The company's growth estimates for the present quarter is a negative 16.2% and positive 660% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Yearly Top and Bottom Value

Moderna's stock is valued at $144.75 at 10:51 EST, way under its 52-week high of $178.50 and way above its 52-week low of $17.68.

Moderna's Moving Average

Moderna's value is way above its 50-day moving average of $115.83 and way above its 200-day moving average of $80.31.

Previous days news about Moderna

Moderna shot expected to bolster U.S. vaccine efforts. According to The Wall Street Journal on Fri Dec 18, "Moderna's vaccine has easier storage and handling requirements and will be shipped in smaller quantities, health officials say. ", "Moderna expects to add 20 million doses of its vaccine to Pfizer's expected U.S. supply of 25 million in December."

Moderna authorization bid to get quick FDA attention, hahn says. According to Bloomberg Quint on Fri Dec 18, "The regulator last week authorized a vaccine from Pfizer Inc. and BioNTech SE for emergency use and its advisers voted 20 to 0, with one abstention, in favor of granting the same status to Moderna's.", "The regulator told Moderna "that it will rapidly work toward finalization and issuance of an emergency use authorization," Hahn said late Thursday in a statement. "

FDA speeds toward Moderna vaccine authorization as soon as today. According to Bloomberg Quint on Fri Dec 18, "Moderna's vaccine is expected to play an important role in the government's plans for mass immunization and slowing the pandemic. ", "Between Pfizer and Moderna, up to 20 million people in the U.S. are expected to get their first shots by year-end."

Moderna shot cleared in U.S., boosting immunization effort. According to Bloomberg Quint on Sat Dec 19, "Bloomberg has previously reported that Moderna hopes to start offering the vaccine to those volunteers within one to two weeks of emergency authorization, according to a letter to some trial participants.", "Moderna's vaccine is 94.1% effective at preventing symptomatic cases of Covid-19 and was able to prevent the most severe infections, according to the FDA's analysis of clinical-trial results. "

Moderna, exxon, Alphabet, Amazon: stocks that defined the week. According to The Wall Street Journal on Sat Dec 19, "Moderna, a ten-year-old biotech that has never had a product cleared by the FDA, expects to deliver a total of 20 million doses by the end of December. ", "U.S. health regulators late Friday permitted use of Moderna's Covid-19 vaccine, the second shot to get the green light to help end the pandemic. "

Statement on the U.S. authorization of the Moderna Covid-19 vaccine. According to Business Insider on Sat Dec 19, "OTTAWA, ON, Dec. 18, 2020 /CNW/ -Health Canada is aware that the U.S. Food and Drug Administration has issued an emergency use authorization for a COVID-19 vaccine manufactured by Moderna.", "Health Canada has been reviewing Moderna's vaccine since it was submitted on October 12, 2020, and is expediting the review of COVID-19 vaccines. "

Moderna to begin delivery; london lockdown ordered: virus update. According to Bloomberg Quint on Sat Dec 19, "The MHRA also "already started a rolling review to assess" Moderna's Covid-19 vaccine "to make sure it meets strict standards on safety, quality and effectiveness," said Nadhim Zahawi, minister for Covid Vaccine Deployment, on Twitter. ", "United Parcel Services will truck the newly-approved Moderna vaccine beginning Sunday morning from Mckesson's Kentucky facility to the courier's nearby main U.S. air hub in Louisville, Kentucky. "

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com